Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × etoposide phosphate × Clear all

Phase

Status

Terminated 2 Withdrawn 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 2 Recurrence 1 Ovarian Neoplasms 1 Ovarian Germ Cell Cancer 1 Nervous System Neoplasms 1 Medulloblastoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Glioma 1 Ganglioneuroblastoma 1 Ependymoma 1 Diffuse Intrinsic Pontine Glioma 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1 Brain Diseases 1

Interventions

venetoclax 19 Cyclophosphamide 17 pembrolizumab 15 Dexamethasone 14 Cytarabine 12 fludarabine 11 Azacitidine 10 Gemcitabine 9 pomalidomide 7 Rituximab 7 Carboplatin 7 selinexor 6 glofitamab 6 Temozolomide 6 Lenalidomide 6 Granulocyte Colony-Stimulating Factor 6 fludarabine phosphate 5 Paclitaxel 5 Oxaliplatin 5 Injections 5 Cisplatin 5 zanubrutinib 4 ruxolitinib 4 obinutuzumab 4 daratumumab 4 carfilzomib 4 Surgical Procedures, Operative 4 Nivolumab 4 Decitabine 4 Cladribine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡